Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.64M | 3.62M | 3.82M | 4.32M | 3.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.80M | 12.74M | 12.26M | 10.35M | 7.13M |
| Operating Income | -10.80M | -12.74M | -12.26M | -10.35M | -7.13M |
| Income Before Tax | -10.00M | -11.89M | -11.35M | -10.20M | -22.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.00M | -11.89M | -11.35M | -10.20M | -22.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.00M | -11.89M | -11.35M | -10.20M | -22.03M |
| EBIT | -10.80M | -12.74M | -12.26M | -10.35M | -7.13M |
| EBITDA | -10.79M | -12.74M | -- | -- | -- |
| EPS Basic | -0.51 | -0.64 | -0.61 | -2.52 | -16.28 |
| Normalized Basic EPS | -0.32 | -0.40 | -0.38 | -1.57 | -10.18 |
| EPS Diluted | -0.51 | -0.64 | -0.61 | -2.52 | -16.28 |
| Normalized Diluted EPS | -0.32 | -0.40 | -0.38 | -1.57 | -10.18 |
| Average Basic Shares Outstanding | 19.45M | 18.70M | 18.70M | 4.05M | 1.35M |
| Average Diluted Shares Outstanding | 19.45M | 18.70M | 18.70M | 4.05M | 1.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |